NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 358 filers reported holding NOVOCURE LTD in Q4 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $245,869 | -4.7% | 3,352 | -1.2% | 0.00% | 0.0% |
| Q3 2022 | $258,000 | +20.0% | 3,394 | +9.6% | 0.00% | 0.0% |
| Q2 2022 | $215,000 | -14.0% | 3,096 | +2.7% | 0.00% | 0.0% |
| Q1 2022 | $250,000 | -12.0% | 3,016 | -20.3% | 0.00% | 0.0% |
| Q4 2021 | $284,000 | -34.4% | 3,782 | +1.4% | 0.00% | 0.0% |
| Q3 2021 | $433,000 | -43.9% | 3,729 | +7.2% | 0.00% | -50.0% |
| Q2 2021 | $772,000 | +259.1% | 3,479 | +114.1% | 0.00% | +100.0% |
| Q1 2021 | $215,000 | -68.7% | 1,625 | -59.1% | 0.00% | -50.0% |
| Q4 2020 | $687,000 | +175.9% | 3,972 | +7.3% | 0.00% | +100.0% |
| Q1 2020 | $249,000 | -40.3% | 3,702 | -25.2% | 0.00% | -50.0% |
| Q4 2019 | $417,000 | +19.8% | 4,952 | +6.4% | 0.00% | 0.0% |
| Q3 2019 | $348,000 | -57.0% | 4,652 | -72.3% | 0.00% | -50.0% |
| Q1 2019 | $809,000 | -49.7% | 16,800 | -45.3% | 0.00% | -50.0% |
| Q3 2018 | $1,609,000 | – | 30,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |